-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, QQZdfhn2mleek13D+YGuIJRLmmSI6BGgUPzT+yDoeysUVw9z08hSlSqziLWXiUiW yJFV8wkAxFzMBxP0Lrnqaw== 0001013708-97-000062.txt : 19970606 0001013708-97-000062.hdr.sgml : 19970606 ACCESSION NUMBER: 0001013708-97-000062 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 19970603 ITEM INFORMATION: Other events FILED AS OF DATE: 19970605 SROS: NASD FILER: COMPANY DATA: COMPANY CONFORMED NAME: MEDIZONE INTERNATIONAL INC CENTRAL INDEX KEY: 0000753772 STANDARD INDUSTRIAL CLASSIFICATION: WHOLESALE-DRUGS PROPRIETARIES & DRUGGISTS' SUNDRIES [5122] IRS NUMBER: 870412648 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 002-93277-D FILM NUMBER: 97619818 BUSINESS ADDRESS: STREET 1: 123 E 54TH ST 7B CITY: NEW YORK STATE: NY ZIP: 10022 BUSINESS PHONE: 2124210303 FORMER COMPANY: FORMER CONFORMED NAME: MADISON FUNDING INC DATE OF NAME CHANGE: 19860413 8-K 1 CURRENT REPORT ON FORM 8-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 CURRENT REPORT ON FORM 8-K Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: June 3, 1997 (Date of Earliest event reported) ******************************* MEDIZONE INTERNATIONAL, INC. ---------------------------- (Exact name of Registrant as specified in its charter) Nevada 2-93277-D 87-0412648 State of Commission IRS Taxpayer Incorporation Registration No. I.D. Number 21 Cummings Park, Suite 274, Woburn, Massachusetts 01801 -------------------------------------------------------- Address of Principal executive offices Registrant's telephone number: (617) 908-6366 -------------- Item 5. Other Events ------------ Medizone International, Inc. (the "Registrant") announced today that during its investigation into the conduct of the Registrant's operations during the tenure of Joseph S. Latino, Ph.D. as the Registrant's Chairman, President and Director of Research, it learned that human trials of the Registrant's ozone therapy on patients infected with either Acquired Immunodeficiency Syndrome (AIDS) or Hepatitis B (chronic active) at the University of Naples had not been authorized by, or commenced at, that institution. The Registrant intends to make corrective disclosure in an amendment to its Form 10K for the period ended December 31, 1996 as soon as its audit for the year is completed. SIGNATURES ---------- Pursuant to the requirements of the Securities Act of 1934, the Registrant has duly caused this Current Report to be signed on its behalf by the undersigned, one of its officers thereunto duly authorized. Dated: New York, NY June 4, 1997 MEDIZONE INTERNATIONAL, INC. By: s/Kenneth Gropper ------------------------------------ Kenneth Gropper -----END PRIVACY-ENHANCED MESSAGE-----